Introduction: Multicenter clinical trials of high-acuity, low-frequency emergencies are expensive and resource intensive. Current standards for trial preparation have significant limitations. Our objective is to describe our use of in situ simulation (ISS) to identify and mitigate threats to enrollment, protocol adherence, and patient safety in preparation for a multicenter clinical trial of antiepileptics for status epilepticus in the emergency department. Methods: This is a descriptive study of ISS conducted in the emergency department at a free-standing, academic pediatric institution. We designed two scenarios, one for an eligible and ineligible patient, to allow care teams to complete all study procedures. All study training was completed before the first ISS. Participants included physicians, nurses, patient care assistants, paramedics, research coordinators, and pharmacists. Ten-minute simulations were followed by 10-minute debriefings, led by trained facilitators using a standard template. Data on threats to enrollment, protocol adherence, and patient safety were recorded. Mitigation strategies were developed by the study team and local experts in ISS. Results: Ten of 18 planned simulations were conducted. Seven of 10 completed simulations were study eligible patients, with 73 total participants. Nine threats to enrollment and five to protocol adherence were identified. Five of 14 were also threats to patient safety. Mitigation strategies included creation of decision aid tools, targeted education during debriefings, adapting study material for use, and revision of status epilepticus treatment algorithm. Conclusions: The addition of ISS to standard preparation for a multicenter clinical trial facilitated the identification and mitigation of threats to study participation and patient safety.
Multiple centers are often required to achieve an adequate sample size, increasing the likelihood of inconsistencies in study conduct and protocol deviations. Participation in a clinical trial in an emergency setting may involve novel interventions and procedures for a given center, increasing the risk of suboptimal care in the emergent setting. When a clinical trial is funded to investigate an intervention for a pediatric emergency, extraordinary and effective preparation is needed to optimize enrollment, protocol adherence, and patient safety.
High-acuity, low-frequency emergencies present unique and formidable challenges to reliable, high-quality care. [3] [4] [5] [6] There is an analogous problem for clinical trials of high-acuity, lowfrequency emergencies. The infrequent presentation of eligible patients, the narrow timeframe to conduct study procedures, and the emergent nature of the situation may increase the likelihood of missing eligible patients and important protocol deviations that might also lead to patient harm. Aspects of standard preparatory and monitoring processes for clinical trials, eg, institutional review board review and data safety monitoring, are intended to optimize enrollment, protocol adherence, and patient safety. However, when an eligible patient presents, study training may have been so remote that, even if it was of the highest quality, providers responsible for enrollment and protocol adherence may struggle to recall the study itself, relevant eligibility criteria, and critical aspects of the study protocol. Moreover, again because of the relative infrequency of both pediatric emergencies and relevant clinical trial experience, many of the most important threats to trial participation may be latent, with important nuances in a given center participating in a multicenter trial. In situ simulation (ISS) has been demonstrated to be an important and effective tool in medical education, systems integration, and clinical research. 3, 7, 8 In situ simulation has specific advantages over other approaches to education, clinical research, and quality improvement, in particular increasing the frequency of high-acuity, low-frequency emergencies. [4] [5] [6] 9, 10 As an adjunct to the standard educational and preparatory activities, ISS may be a uniquely powerful approach to enhance enrollment and protocol adherence and improve patient safety by both accurately characterizing latent threats in a given center and acting as a vehicle to directly mitigate the same threats. In situ simulation could also be used after enrollment begins to maintain pretrial levels of knowledge and awareness. Figure 1 is a flow diagram that illustrates this framework of using ISS to enhance the preparatory process and systems integration for a clinical trial.
The objective of the current report is to describe our use of ISS to augment the standard pretrial preparatory activities before our site's participation in a multicenter clinical trial. To our knowledge, there are no published reports of the use of ISS to enhance preparation in a clinical trial. We specifically sought to use simulation to allow for identification of latent threats-threats that were not identified or were poorly characterized after completion of the standard study training. We hypothesized that ISS would uniquely enhance the identification and mitigation of threats to enrollment, protocol adherence, and patient safety that were insufficiently addressed through the standard educational efforts.
METHODS

Setting and Simulation Participants
The setting for both the clinical trial and the ISSs was the resuscitation area of a pediatric ED at a free-standing, academic, pediatric institution. Of the 90,000 combined annual visits, 4100 (4.6%) patients are evaluated for medical (2000) and traumatic (2100) emergencies in the resuscitation area. Designated care teams evaluate and manage all patients with medical emergencies, led by a physician board-certified in pediatric emergency medicine (PEM) or a PEM fellow. Team members also include nursing team leaders, bedside and medication nurses, a respiratory therapist, a pediatric resident, and a paramedic or patient care assistant. The participants in the study-related simulations were the providers staffing the pediatric ED and designated to respond to the resuscitation area. The clinical research coordinators (CRCs) also participated in these simulations. Before commencement of the study-related simulations, all PEM attendings, fellows, and CRCs received formal study training. The study protocol for Established Status Epilepticus Treatment Trial (ESETT) was approved by our institutional review board. The protocol for the current study was submitted to the institutional review board as an amendment to the ESETT study and was approved.
The Medical Resuscitation Committee
The medical resuscitation committee (MRC) at our institution is responsible for peer review, quality assurance/ improvement, and clinical research for patients evaluated for medical emergencies in the resuscitation area of our institution's pediatric ED. A central aspect of the MRC's work is oversight of an ISS program for the ED resuscitation area, which was developed to identify latent safety threats and enhance quality assurance and educational activities for low-frequency, highacuity medical emergencies. All MRC simulation facilitators have been formally trained through the simulation center. The MRC schedules an average of seven simulations per month; in 2017, 38 (46%) of 83 simulations were completed. Standard cancelation criteria include high ED volume or patient acuity, a patient being actively evaluated in the resuscitation area, and inadequate ED staffing. 
Clinical Trial
The ESETT is a multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the emergency department (ED) treatment of pediatric and adult patients with benzodiazepine-refractory status epilepticus (SE; sponsored by National Institute of Neurological Disorders and Stroke 1 U01 NS088034 01, ClinialTrials.gov ID NCT01960075). [11] [12] [13] The goals of the study are to determine the effectiveness and safety of these drugs. There are 56 sites in total that are enrolling for ESETT-43 adult centers from the Neurological Emergencies Treatment Trials Network and 15 pediatric centers from the Pediatric Emergency Care Applied Research Network. The ESETT is an example of a clinical trial that involves prospective enrollment of a patient with a high-acuity, low-frequency medical emergency, as the annual incidence of SE has been estimated to be 41 to 61 per 100,000 patients in all age groups.
14 Thus, at any one center, a precious few eligible patients can be expected to present each year. For example, in our pediatric ED during 2015 (before study commencement), only 20 patients potentially eligible for ESETT were evaluated.
The primary objective of ESETT is to determine the most effective and/or the least effective treatment of benzodiazepinerefractory SE. [11] [12] [13] There are three active treatment arms: fosphenytoin, levetiracetam, and valproic acid. The primary outcome is clinical cessation of SE, determined by the absence of clinically apparent seizures and improving responsiveness, at 60 minutes after the start of study medication infusion, without the use of additional antiepileptic drugs. See Table 1 for inclusion criteria. The ESETT enrollment occurs under exception from informed consent rules (EFIC), due to the emergent and life-threatening nature of SE.
Trial Preparation
All site investigators received formal, in-person training at an investigator meeting before study commencement. Templates of study educational materials were supplied by the lead investigative team, but dissemination of these materials and the site's approach to prestudy education and training was left to the discretion of the site investigator. All CRCs responsible for ED patient enrollment processes were trained extensively on study procedures, both in small group and one-on-one settings. Mandatory education was assigned to all ED nursing staff, and successful completion of a posttest was required before the first patient enrollment. In addition, a separate presentation was given to nurse team leaders by the site investigator, because this group exclusively fills the nurse team leader role in the resuscitation area and functions as co-team leaders with the PEM attending. Study training for the PEM attendings and fellows included the following: (1) a presentation at our divisional staff meeting, (2) review of the same presentation via an all-staff e-mail, and (3) individual, in-person training with the site investigator. All PEM attendings and fellows completed at least one of these activities. Our pediatric ED pharmacist participated in the design of the study-related educational efforts, including the ordering and administration of the study drug.
Before the ISSs, we developed a written document to assist providers in determining patient eligibility and in adhering to the study protocol. We adapted standard study materials and placed the two-page document in a binder located in each trauma bay computer cart. The two-page document (see Text Document, Supplemental Digital Content 1, which shows instructions for enrollment; http://links.lww.com/SIH/A382) included the following: (1) study inclusion and exclusion criteria, (2) a chart for adequate dosing of benzodiazepines, (3) a chart for dosing of the study medication, (4) the definition of complications related to the study medication, ie, hypotension, (5) contact information for the site investigators, (6) instructions on how to administer the study medication, and (7) a diagram for ordering the study medication in the electronic medical record (EMR). We also loaded a dosing calculator for determining medication-related inclusion criteria on all trauma bay computers. Both the binder and dosing calculator were included/tested during the ISSs, with refinements made based on findings from the simulations.
Integration of the Trial Into Clinical Care
Treatment algorithms are used in our resuscitation area to help guide physicians in the management of certain high-risk, low-frequency conditions. New publicized guidelines about the acute management of the study-related condition, SE, and findings from the simulations were used to inform the revision of our department's treatment algorithm for SE. A highlighted box was embedded in the algorithm at the point where enrollment in the trial should be considered if the patient met eligibility criteria (eg, if the seizure was refractory to initial benzodiazepines).
Study-Related Simulation Scenarios
The MRC and site investigators designed two study-related scenarios (see Text Document, Supplemental Digital Content 2, which shows the simulation scenario; http://links. lww.com/SIH/A383), one for an eligible patient and one for an ineligible patient. To ensure that the most critical study steps would be attempted by providers and observed by study staff, the enrollment-eligible scenario was designed to encourage ED care providers to complete all study-related procedures through study drug administration ( Table 2 ). The scenarios were developed using the MRC's standard process, including being edited and vetted by the full committee. The scenarios were not pilot tested, however, as the scenarios were adapted from a SE scenario used previously by the committee.
The study-related simulations were scheduled for either 9:00 AM to 12:30 PM or at 4:30 PM, to target both first-and second-shift providers, respectively, as these were the shifts where CRCs would be present to enroll. Each simulation session was limited to 20 to 10 minutes for the simulation and 10 minutes for debriefing. All participants received a standard prebrief before the start of each simulation, which included orientation to the environment and the simulator as well as a scripted introduction to the simulation scenario. A site investigator, lead CRC, MRC physician, and nursing facilitator led the team debriefing. The debriefings were focused on discussing ESETT study procedures, emphasizing threats identified in the current and any previous simulations. Specific efforts to mitigate those threats, eg, modifications to the two-page document in the study binder, were emphasized. Medical management of SE was discussed when relevant to both the ESETT study procedures and our site's treatment protocol for SE (see hereinafter).
Data Collection
We created a standard debriefing template (see Text Document, Supplemental Digital Content 3, which is an example of the debriefing template; http://links.lww.com/SIH/A384) for the study-related simulations, based on the template used by the MRC for its in situ program. The debriefing template highlighted threats identified during previous simulations, ongoing mitigation efforts, and key points relevant to our site's SE algorithm. The two MRC facilitators (physician and nurse) present at each study-related simulation were responsible for collecting relevant data using the template, based on direct observation only. The MRC nurse was the primary documenter, recording potential threats identified in the simulation or debriefing. The MRC physician facilitator then reviewed the debriefing record for completeness. These records were disseminated to the MRC and site investigators, who met regularly to review findings from the simulations and plan subsequent simulations/mitigation efforts.
Outcomes
The main outcomes of the current report were (1) the threats to enrollment, protocol adherence, and patient safety identified during the simulations and (2) our efforts to mitigate each threat. Threats were defined as latent, system-based threats that might be actualized for a given patient at any time and contribute to errors in study enrollment, protocol adherence, or patient safety. 15 Mitigation strategies were developed, implemented, and refined iteratively after each simulation. A given threat could be identified during multiple simulations, but the intent was to eliminate the threat entirely before the next simulation (latent threats) or decrease its risk through dissemination to ED care providers (knowledge deficit).
After completion of the simulations, the MRC and site investigators reviewed all simulation notes to determine study outcomes by consensus. A secondary goal of our work was to revise our existing algorithm for the treatment of SE before study initiation, leveraging our findings from the study-related simulations and recently published guidelines on SE treatment. The new guidelines and the ESETT protocol deviated significantly from our existing guideline, so we anticipated that this would be a threat to enrollment. We revised our existing algorithm to optimize study participation and patient safety, because use of the algorithm was standard practice before study commencement.
Analysis
We tabulated both outcomes and report each descriptively.
RESULTS
Simulations From October to December 2015 (study commencement in late December 2015), we completed 10 of 18 scheduled study-related simulations (56%). Seven of the completed simulations were for eligible patients and three for ineligible. Reasons for cancelation were ED staffing issues, high ED volume, and the presence of an actual patient in the resuscitation area. A total of 73 individual providers (43 nurses, 8 physicians, 3 patient care assistants, 3 paramedics, and 16 CRCs) participated in the seven study-related simulations, representing approximately 25% of all ED providers at our site.
Main Outcomes
The definitions of each threat to enrollment, protocol adherence, and patient safety as well as our mitigation strategies in response to each threat are presented in Tables 3 and 4 , respectively. Mitigation strategies were implemented immediately after a threat was identified and those strategies were reinforced in subsequent simulations. Table 5 lists the specific threats identified in each simulation as well as the total number of threats identified.
The most common threat to enrollment was provider confusion about the eligibility criteria, particularly the dosing and timing of benzodiazepines. This threat was identified in the first ISS and in four of the seven total simulations conducted. The protocol lists three potential benzodiazepines in the eligibility criteria, each with a different adequate dose. To mitigate this risk, we created a benzodiazepine dosing chart to aid providers in determining whether the patient received an adequate dose. This chart was placed in the resuscitation area where enrollments would occur. We also installed a benzodiazepine dosing calculator, provided by the study team, on all the computers in our resuscitation area used by the documenting nurse. In subsequent debriefings, we emphasized that at least one benzodiazepine must be administered by a medical provider, which includes prehospital providers. Finally, we stressed that the timing of benzodiazepine administration is important, in that it has to be more than 5 minutes but less than 30 minutes from enrollment.
During the simulations, care providers were concerned about the consent process, which is a threat to enrollment. This threat was identified in the second simulation conducted. This was the first time our department participated in a study using EFIC that required a bedside intervention. During simulations, providers were educated about EFIC and the necessity Outside simulation/debriefing: We placed in the trauma bay a template for ED providers to explain EFIC to the family. We also included a list of patients who had opted out before study commencement. The availability of both was also mentioned in subsequent debriefings. The lead CRC reviewed threats identified in the simulations with all CRCs during biweekly meetings. "Study": Commonly used phrases " study medication" or "ESETT study" -The use of the term "study" could cause parental concern about enrollment and their child receiving experimental treatment.
Lack of comfort and unfamiliarity with clinical trials in the resuscitation area during a medical emergency.
Subsequent simulation/debriefing:
In subsequent simulations, we encouraged use of the term "ESETT protocol" and avoidance of "study."
Intubation: How tracheal intubation affects eligibility for enrollment, before or after study medication infusion Sedatives used for RSI have anti-epileptic properties, affecting eligibility, and the neuromuscular blockers affect determination of primary outcome.
In subsequent simulation debriefings, we clarified that intubation before study medication infusion excludes the patient from enrollment but that that potential need for intubation should not preclude enrollment.
All CRCs attended at least 1 subsequent ISS and practiced determining eligibility. Outside simulation/debriefing: The lead CRC reviewed threats identified in the simulations with all CRCs during biweekly meetings. Benzo types: Which benzodiazepines could be administered before enrollment Many benzodiazepines are used to treat seizures and inadequacy of standard study education and training
We emphasized that the eligible benzodiazepines are midazolam, lorazepam, and diazepam. All CRCs attended at least 1 subsequent ISS and practiced determining eligibility. Outside simulation/debriefing: We included eligibility criteria in the study folder. The lead CRC reviewed threats identified in the simulations with all CRCs during biweekly meetings. Benzo timing: Timing of benzodiazepine administration before enrollment Eligibility criteria for the timing of benzodiazepine administration were inherently confusing (a specific time range rather than a single time point) and inadequacy of standard study education and training.
We emphasized that the last dose of benzodiazepine had to have been administered at least 5 min but not longer than 30 min before study enrollment. All CRCs attended at least 1 subsequent ISS and practiced determining eligibility. Outside simulation/debriefing: We included eligibility criteria in the study folder.
of EFIC for a pediatric emergency trial. Providers and research coordinators expressed apprehensions about approaching families whose child was enrolled in a study with EFIC. This led to the creation of a short written template to help providers introduce the study to the family before the CRC going in to speak to the family and obtain informed consent. In addition, we encouraged providers to use phrases such as "ESETT protocol" as opposed to using words such as "study," "enrollment," or "investigational" in front of families until the study has been introduced.
The most common threat to protocol adherence is the detection of and response to hypotension. This threat was identified in the second simulation conducted and in five of the seven total simulations. Definitions for hypotension differ by age, which lead to provider confusion. In addition, providers were unsure of how to treat hypotension in the setting of an unknown study medication. We created a chart with age-specific thresholds of hypotension and placed it in the study folder in the resuscitation area. We also provided targeted education and clarification during simulation debriefings that providers should slow the rate of infusion of the study medication by half if hypotension is present.
Common threats to protocol adherence were confusion about the preparation and administration of the study medication. These threats were identified in the second simulation conducted and in four of the seven total simulations. The ESETT Manual of Operations specifies to directly administer the study medication from the study vial and not to flush the intravenous (IV) tubing, because extra medication in the line was built into the calculated dose. This deviates from our standard approach in the resuscitation area, which involves first drawing the exact dose from the vial and then administering it using an infusion pump. We also identified threats related to calibrating the infusion pump (to administer the correct volume for 10 minutes) and to flushing the IV tubing after completion of medication (standard practice in our ED). During subsequent debriefings, these issues were emphasized and explicitly discussed with the participating ED nurses. The lead CRC and MRC nurse facilitator frequently spent additional time practicing medication preparation and administration with the participating nurses.
DISCUSSION
Participation in prestudy education and training activities is a ubiquitous and common experience in academic medicine. The typical approaches to trial preparation include didactic, slide-based presentations, e-mail of the presentation slides for self-review, online learning modules, and/or one-to-one training with the principal investigator. Training may also include periodic reminders via e-mail and discussions at staff meetings or fliers posted in the study setting, both highlighting 
Subsequent simulation/debriefing:
We created and installed a benzodiazepine dose calculator on the computers in our resuscitation area and had participating providers practice using the dose calculator during simulation debriefings. All CRCs attended at least 1 subsequent ISS and practiced determining eligibility. Outside simulation/debriefing: We included eligibility information related to benzodiazepine dosing available in the study folder, which contained a chart to help providers determine adequate dosing. The lead CRC reviewed threats identified in the simulations with all CRCs during biweekly meetings. Prehospital benzos: Who could administer benzodiazepines before enrollment Eligibility criteria inherently confusing (benzodiazepines could be given by caregivers at home or by prehospital providers before arrival at our ED) and inadequacy of standard study education and training.
In subsequent simulation debriefings, we clarified that all benzodiazepines administered within the past 30 min can be added up in the cumulative dosing but one of them has to be given by a medical provider (ie, prehospital provider or in the ED). Benzodiazepines given by parents can count toward adequate dosing. SE algorithm: Existing site-specific algorithm for treatment of SE recommended only fosphenytoin as the second-line agent of choice* Fosphenytoin is the historical standard second-line medication to treat SE in our ED, and providers frequently use the SE algorithm as a decision aid. The algorithm did not reflect the clinical equipoise that existed among the second-line medications.
We encouraged providers to use a revised version of the SE algorithm during the simulation and highlighted the revisions during the debriefing. Outside simulation/debriefing: We revised our SE algorithm to incorporate the ESETT study as well as the most recent treatment guidelines. The revised guideline was presented at division staff meeting.
key issues with patient enrollments. There is published evidence demonstrating that inadequate approaches to randomized clinical trial design and execution may increase bias in treatment effects, 16 but the relevant literature is sparse on the effectiveness and specific limitations of the common approaches to study preparation. 17 The United States Food and Drug Administration formed the Clinical Trials Transformation Initiative to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. 18 The Clinical Trials Transformation Initiative provide tools to investigators for improvement in recruitment, informed consent process, and study design, but there is no mention of the use of ISS as a tool for improving clinical trials. Our experience in an academic, pediatric setting is that study preparation efforts are often inadequate. Compounding the issues is the rarity of many pediatric illnesses and injuries, especially medical emergencies, which further limits opportunities for providers to practice enrollment and study procedures, especially in high-volume settings where the exposure of individual providers may be rare.
In the current study, we were able to practice study enrollment, identifying specific threats ourselves, often across multiple simulations. We were then able to design mitigation strategies for specific threats and test them before study commencement. Subsequent simulations were also iterative and cumulativewe not only focused on threats that were identified during that particular simulation but also reiterated threats identified in previous simulations. Second, analogous to systems integration, we were able to integrate the study protocol with our existing treatment algorithm, possibly improving both our care of these patients and our participation in the clinical trial. Third, ED providers and research staff had opportunities to practice enrollment, potentially increasing study knowledge, comfort, and awareness.
The addition of ISS to site preparation for participation in a multicenter clinical trial enhanced the identification and mitigation of threats to enrollment, protocol adherence, and patient safety that were inadequately addressed by the standard approach. In situ simulation specifically allowed the efficient and iterative "testing" of providers and environment, permitting the identification and characterization of various threats while acting as both a mechanism to educate participants and refine study tools designed to improve enrollment and protocol adherence. We completed 10 simulations for a 3-month period, whereas for the first 25 months of trial participation, our site saw approximately one eligible patient every 2 months. Moreover, rather than waiting until errors were made for actual patient enrollments, those same errors could be made during simulations and efforts made to mitigate the risk for actual patients. Given their infrequency and the challenges of data collection, relying on actual patient encounters to identify latent threats is likely inefficient, inaccurate, and unsafe. Dissemination of the results of the simulations to all ED providers, We worked with our investigational pharmacy to create an order for the study medication in our EMR. We also created a laminated instruction sheet with pictures to help providers order the study drug and placed it in the study folder. We presented the order entry instructions at a meeting of the nurse team leaders. Med preparation: Method of medication preparation different than standard practice* Standard practice at our institution for medication administration is to draw up the dose into a syringe and administer via a pump. The study protocol requires spiking the medication bottle directly.
We reviewed the approach to study drug preparation. For several debriefings, the MRC nurse facilitator practiced medication preparation with the participating nurses. Outside simulation/debriefing: In collaboration with our ED pharmacist and nurse team leaders, we standardized the medication administration to be run directly from the bottle in which it was originally packaged, as opposed to being drawn up into a syringe. We presented the approach to study drug preparation at a meeting of the nurse team leaders. Med administration: Method of medication administration different than standard practice* Standard practice in our ED is to flush tubing or administer chase fluid after infusion of a medication is complete, to ensure the entire volume is administered.
Outside simulation/debriefing: Through mock infusions, we determined that it was not necessary to flush the tubing after the infusion of the study drug was completed because extra medication was built into the calculated dose. Co-administration: Safety of co-administration of study drug with normal saline *
Lack of clarity in the ESETT Manual of Procedures Outside simulation/debriefing:
In collaboration with our ED pharmacist, we determined that it was safe to infuse the study drug with normal saline. We emphasized this point in subsequent simulation debriefings. Hypotension: Risk of not detecting life-threatening hypotension and cardiac arrhythmia (key secondary outcomes)* There are many definitions of hypotension that vary by patient age and size. For patients in SE, blood pressure monitoring may be infrequent, and awareness of heart rhythm may be low.
Subsequent simulation/debriefing:
We reinforced the potential adverse effects of study drug infusion and the importance of frequent vital signs for data collection. We highlighted that there was a reference for hypotension in the study folder.
emphasizing the specific threats identified and efforts to mitigate them, was a more effective approach than general updates that lacked specificity to the actual system and the threats most likely to cause errors.
Limitations
This was a descriptive report of our initial efforts to incorporate simulation into the preparatory education and training before participation in a multicenter, therapeutic trial of a relatively uncommon pediatric emergency. As such, we cannot determine the independent effects of ISS on our preparatory process, in particular in comparison with a standard approach alone. It is possible that other forms of simulation or nonsimulationbased activities might work as well and with lower costs. However, ISS has significant advantages over other forms of simulation for clinical research, education, and systems integration, and it is reasonable to assume that ISS has analogous advantages for clinical trial preparation. Second, because this was our first use of ISS for trial preparation and our primary objective was optimizing preparation rather than studying the effects of simulation, our approach lacked rigor, especially in data collection. Future studies should focus on the specific contributions of ISS compared with the standard approach. Consideration should be given to the costs associated, especially in centers without existing simulation programs.
Future Directions
After study commencement, we planned to include regular study-related simulations in our ISS program, both because improving the treatment of SE was a primary goal of this program and to maintain staff awareness of and familiarity with study procedures to facilitate ongoing mitigation of threats. Between January 2016 and June 2017, we completed 15 (50%) of 30 planned simulations. We continued to perform structured debriefs and collect data on threats and key protocol deviations. The following are the threats identified in these subsequent simulations with tabulated frequencies in parentheses: med preparation (5), adequate dosing (4), "study" (3), EFIC (2), EMR (2), med administration (2), hypotension (2), and intubation (1) . To further address these threats, most recently we have used ISS to train the physician team leader to determine eligibility and complete study procedures and data collection, as CRCs are not available on third (overnight) shifts. In addition, we continue to update and re-educate the staff with presentations every 6 months.
One of the most significant limitations of our initial study is the lack of data supporting the independent benefit of ISS. To partially address this limitation, which is also an obvious gap in the relevant literature, we plan to complete a second study comparing eligible patient capture and protocol deviations between our site and all other centers participating in ESETT, stratifying by pediatric versus adult/general ED. In discussions with the lead investigators, only one other site used simulation to prepare for the trial, and this effort was neither structured nor ongoing.
In addition, our use of simulation for trial preparation demonstrates that a rigorous simulation program can be an asset to principal investigators designing complex clinical trials. We envision simulation playing a role in trial preparation in future randomized clinical trials that enroll in our ED, especially those with protocols involving conditions that are timesensitive, high acuity, and low frequency.
CONCLUSIONS
The addition of ISS to the standard approach to education and training before participation in a multicenter clinical trial facilitated the identification and mitigation of threats to study participation and patient safety. In situ simulation allowed the mitigation of these latent threats for a shortened period that otherwise would have required errors during actual patient encounters to identify. 
